NEW YORK, NY / ACCESSWIRE / June 22, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Baidu, Inc. (NASDAQ:BIDU)

Investors Affected: March 16, 2019 – April 7, 2020

A class action has commenced on behalf of certain shareholders in Baidu, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Baidu's feed services were not in compliance with applicable Chinese regulatory standards; (ii) the foregoing noncompliance subjected the Company to a heightened risk of regulatory enforcement, including the removal or suspension of certain of Baidu's services and products; (iii) accordingly, the Company's revenues derived from online marketing services were unlikely to be sustainable; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/baidu-inc-loss-submission-form/?id=7461&from=1

Hallmark Financial Services, Inc. (NASDAQ:HALL)

Investors Affected: March 5, 2019 – March 17, 2020

A class action has commenced on behalf of certain shareholders in Hallmark Financial Services, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective internal controls over accounting and financial reporting related to reserves for unpaid losses; (2) the Company improperly accounted for reserve for unpaid losses and loss-adjustment expenses related to its Binding Primary Commercial Auto business; (3) as a result, Hallmark Financial would be forced to report a $63.8 million loss development for prior underwriting years; (4) as a result, Hallmark Financial would exit from its Binding Primary Commercial Auto business; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/hallmark-financial-services-inc-loss-submission-form/?id=7461&from=1

Colony Capital, Inc. (NYSE:CLNY)

Investors Affected: August 9, 2019 – May 7, 2020

A class action has commenced on behalf of certain shareholders in Colony Capital, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Colony's sale of its industrial real estate portfolio and the bifurcation of Colony Credit Real Estate's portfolio were foreseeably likely to negatively impact Colony's financial and operating results; (ii) certain of Colony's remaining portfolio companies carried unsustainable levels of debt secured by hotels and healthcare-related properties and were thus at a significant risk of default; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/colony-capital-inc-loss-submission-form/?id=7461&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

ReleaseID: 594750

NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against SCWorx Corp. ("SCWorx " or "the Company") (NASDAQ:WORX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired SCWorx securities between April 13, 2020 and April 17, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/worx.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) that SCWorx's supplier for COVID-19 tests had previously misrepresented its operations; (2) that SCWorx's buyer was a small company that was unlikely to adequately support the purported volume of orders for COVID-19 tests; (3) that, as a result, the Company's purchase order for COVID-19 tests had been overstated or entirely fabricated; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/worx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in SCWorx you have until June 29, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC

ReleaseID: 594661

NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $6,000,000 Follow-On Offering for Document Security Systems, Inc. (NYSE American:DSS)

About Document Security Systems, Inc.

DSS is a multinational company operating business focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPO's. Its historic business revolves around counterfeit deterrent and authentication technologies, smart packaging, and consumer product engagement. DSS is led by its Chairman and largest shareholder, Mr. Fai Chan, a highly successful global business veteran of more than 40 years specializing in corporate transformation while managing risk. He has successfully restructured more than 35 corporations with a combined value of $25 billion.

About Aegis Capital Corp.

Aegis Capital Corporation is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Aegis Capital Corporation also provides research and sales and trading services to institutional investors. Aegis Capital Corporation was established in 1984 and is headquartered in New York City.

For more information, visit www.aegiscapcorp.com

This communication has been prepared by Aegis Capital Corporation for distribution to Aegis Capital Corporation's clientele. This communication is not intended for public dissemination and the recipient is prohibited from sharing this information. This communication has been prepared for institutional – accounts, as defined within FINRA Rule 4512(c), who (1) are capable of evaluating investment risks independently, both in general and with regard to all transactions and investment strategies involving a security or securities; and (2) will exercise independent judgment in evaluating the recommendations of any broker – dealer or its associated persons. This communication is not a product of Aegis Capital Corporation Research Department. Aegis Capital Corporation., Member FINRA, SIPC

SOURCE: Aegis Capital Corp.

ReleaseID: 594749

NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

DNK Shareholders Click Here: https://www.zlk.com/pslra-1/phoenix-tree-holdings-limited-loss-form?prid=7457&wire=1
WFC Shareholders Click Here: https://www.zlk.com/pslra-1/wells-fargo-company-loss-submission-form?prid=7457&wire=1
ENPH Shareholders Click Here: https://www.zlk.com/pslra-1/enphase-energy-inc-loss-submission-form?prid=7457&wire=1

* ADDITIONAL INFORMATION BELOW *

Phoenix Tree Holdings Limited (NYSE:DNK)

Investors affected purchased American Depositary Shares ("ADS") of Phoenix pursuant and/or traceable to prospectuses and registration statements issued in connection with the Company's January 2020 initial public offering
Lead Plaintiff Deadline: June 26, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/phoenix-tree-holdings-limited-loss-form?prid=7457&wire=1

According to the filed complaint, the documents Phoenix Tree issued in connection with its initial public offering ("IPO") omitted or otherwise misrepresented the nature and level of renter complaints the Company had received before and as of the IPO, as well as the demand in the Chinese residential rental market and the Company's exposure to significant adverse developments resulting from the onset of the coronavirus in China – particularly in Wuhan – at the time of the IPO. After the IPO, reports emerged, indicating that Phoenix was experiencing ongoing problems due to the coronavirus, which was causing financial and other harm to tenants.

Wells Fargo & Company (NYSE:WFC)

WFC Lawsuit on behalf of: investors who purchased April 5, 2020 – May 5, 2020
Lead Plaintiff Deadline: August 3, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/wells-fargo-company-loss-submission-form?prid=7457&wire=1

According to the filed complaint, during the class period, Wells Fargo & Company made materially false and/or misleading statements and/or failed to disclose that: (i) Wells Fargo planned to, and did, improperly allocate government-backed loans under the Paycheck Protection Program ("PPP"), and/or had inadequate controls in place to prevent such misallocation; (ii) the foregoing foreseeably increased the Company's litigation risk with respect to PPP allocation, as well as increased regulatory scrutiny and/or potential enforcement actions; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Enphase Energy, Inc. (NASDAQ:ENPH)

ENPH Lawsuit on behalf of: investors who purchased February 26, 2019 – June 17, 2020
Lead Plaintiff Deadline: August 17, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/enphase-energy-inc-loss-submission-form?prid=7457&wire=1

According to the filed complaint, during the class period, Enphase Energy, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) its revenues, both U.S. and international, were inflated; (2) the Company engaged in improper deferred revenue accounting practices; (3) the Company's reported base points expansion in gross margins were overstated; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
http://www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 594747

SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2020 / Hagens Berman urges investors in Hallmark Financial Services, Inc. (NASDAQ:HALL) who have suffered significant losses to submit their losses now. The July 7, 2020 lead plaintiff deadline in a securities fraud class action against Hallmark is fast approaching.

Class Period: Mar. 5, 2019 – Mar. 17, 2020

Lead Plaintiff Deadline: July 7, 2020

Visit: www.hbsslaw.com/investor-fraud/HALL

Contact An Attorney Now: HALL@hbsslaw.com

844-916-0895

Hallmark Financial Services (HALL) Securities Class Action:

The complaint alleges that throughout the Class Period, Defendants misrepresented and concealed: (1) that the Company lacked effective internal controls over accounting and financial reporting related to reserves for unpaid losses; and (2) that the Company improperly accounted for reserves for unpaid losses and loss-adjustment expenses related to its Binding Primary Commercial Auto business.

Investors began to learn the truth, according to the complaint, through a series of disclosures beginning on Mar. 2, 2020, when Hallmark announced it was exiting the Binding Primary Commercial Auto business and reported a $63.8 million loss development for prior underwriting years.

Then, on Mar. 11, 2020, Hallmark announced it had dismissed its independent auditor BDO over a "disagreement" concerning the Company's estimated reserves for unpaid losses and loss adjustment expenses throughout 2019.

Finally, on Mar. 17, 2020, Hallmark disclosed a letter from BDO to the SEC revealing that BDO had expanded significantly the scope of its audit on Jan. 31, 2020, with respect to the matters of disagreement, and that "a substantial portion the requests had not been received and/or tested prior to our termination."

These disclosures caused Hallmark shares to decline over 75% lower between Mar. 2 and Mar. 18, 2020.

"We're focused on proving Defendants intentionally misled investors about the Company's internal controls and the sufficiency of its loss reserves," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of Hallmark and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Hallmark should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email HALL@hbsslaw.com.

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers, and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news, visit our newsroom or follow us on Twitter at @classactionlaw.

CONTACT:
Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 594744

LOS ANGELES, CA / ACCESSWIRE / June 22, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against Baidu, Inc. ("Baidu" or "the Company") (NASDAQ:BIDU) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 16, 2019 and April 7, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before June 22, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Baidu failed to maintain compliance with Chinese laws and regulations with its feed services. The Company was at a heightened risk of enforcement action by the Chinese government based on the noncompliance. This threat meant that the Company's revenues derived from online marketing were likely not to be sustainable. Based on these facts, the Company's public statements were false and materially misleading. When the market learned the truth about Baidu, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 594742

CEO of MLMC, Jeff Cooley continues to help his local community by providing support in the form of financial aid.

MONROE, MI / ACCESSWIRE / June 22, 2020 / This past month, Ohio-based business owner Jeff Cooley graciously donated $1,000 to the Monroe YMCA. Having graduated from Central Michigan University, the state holds special significance for Cooley. As part of the Detroit-Ann Arbor-Flint combined statistical area, the Monroe YMCA has continued serving its community and providing much-needed support in these unequivocally tough times. In keeping with the 176-year history of the YMCA and its efforts to foster overall health, the Monroe YMCA's key tenets are the promotion of healthy living, youth development, and social responsibility.

Cooley's donation will help the Monroe YMCA to continue sustaining the municipality through socially distanced and sanctioned activities, as well as essential services such as childcare. Additionally, funds received by the Monroe YMCA will work to fund their current collaboration with the Farmers to Families Food Box Coalition – a program that supplies boxes of produce to children and families in need.

If you are in a position to donate to the Monroe YMCA, your contribution will also help provide relief for the nation's most vulnerable. To give back, click the donate button on the Monroe YMCA's webpage: http://www.ymcaofmonroe.org/.

About Jeff Cooley

Jeff Cooley is a professional advisor and investor with more than thirty years of business experience. He began his entrepreneurial career in the marketing department of La-Z-Boy Incorporated, located in Monroe, Michigan. After a few years, Cooley's transition to the Calphalon cookware company, saw him rise the ranks to President & CEO. After Calphalon was acquired by Rubbermaid, Cooley was swiftly promoted to Global President.

Cooley is now self-employed as the CEO & Founder of MLMC, which provides investors with much-needed guidance and pathways towards success. His work as an advisor has allowed Cooley to utilize his hard-earned business acumen and provide fledging businesses with tried and true strategic and financial preparedness.

Contact:

Jeff Cooley
news@jeffcooley.net

SOURCE: Jeff Cooley

ReleaseID: 594741

TORONTO, CANADA / ACCESSWIRE / June 22, 2020 / Route1 Inc. (OTCQB:ROIUF) (TSXV:ROI) (the "Company" or "Route1"), an advanced North American provider of data-centric business empowerment solutions, today reported that it will hold a conference call and web cast to provide a business update on Thursday, July 9, 2020 at 10:00 am eastern.

Participants should dial Toll-Free: 1-877-407-0782 or Toll/International: 1-201-689-8567 at least 10 minutes prior to the conference. For those unable to attend the call, a replay will be available on July 9, 2020 after 4 pm eastern at Toll-Free 1-877-481-4010 or Toll/International 1-919-882-2331, pass code #35491 until 10 am on July 16, 2020.

The webcast will be presented live at https://www.webcaster4.com/Webcast/Page/2167/35491.

About Route1 Inc.

Route1 Inc., also operating under the tradenames GroupMobile and PCS Mobile, is an advanced North American technology company that empowers their clients with data-centric solutions necessary to drive greater profitability, improve operational efficiency and gain sustainable competitive advantages, while always emphasizing a strong cybersecurity and information assurance posture. Route1 delivers exceptional client outcomes through real-time secure delivery of actionable intelligence to decision makers, whether it be in a manufacturing plant, in-theater or in a university parking lot. Route1 is listed on the OTCQB in the United States under the symbol ROIUF and in Canada on the TSX Venture Exchange under the symbol ROI. For more information, visit: www.route1.com.

For More Information, Contact:

Tony Busseri
Chief Executive Officer
+1 416 509 1496
tony.busseri@route1.com

This news release, required by applicable Canadian laws, does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

© 2020 Route1 Inc. All rights reserved. No part of this document may be reproduced, transmitted, or otherwise used in whole or in part or by any means without prior written consent of Route1 Inc. See https://www.route1.com/terms-of-use/ for notice of Route1's intellectual property.

This news release may contain statements that are not current or historical factual statements that may constitute forward-looking statements. These statements are based on certain factors and assumptions, including, price and liquidity of the common shares, expected financial performance, business prospects, technological developments, and development activities and like matters. While Route1 considers these factors and assumptions to be reasonable, based on information currently available, they may prove to be incorrect. These statements involve risks and uncertainties, including but not limited to the risk factors described in reporting documents filed by the Company. Actual results could differ materially from those projected as a result of these and other risks and should not be relied upon as a prediction of future events. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events, except as required by law. Estimates used in this presentation are from Company sources. Past performance is not guarantee of future performance and readers should not rely on historical results as an indication of future results.

SOURCE: Route1 Inc.

ReleaseID: 594738

NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Medical gowns are one of the most important pieces of personal protective equipment in the fight against COVID-19. In order to protect themselves from the coronavirus and other pathogens, frontline healthcare workers need medical gowns along with masks, plastic face shields, booties and other protective equipment. Without the disposable gowns, doctors, nurses, lab technicians and cleaners put themselves and their patients at risk. Unfortunately, there has been a serious shortage of the medical gowns due to increased global demand. One company, Sultan Capital Group, has stepped up to address the shortage.

Sultan Capital Group LLC. was founded five years ago and operates two ultra modern and sanitary manufacturing facilities in Moldova and Bangladesh. The facilities which specialize in FDA approved and testing medical gowns, have been ramping up production of personal protective equipment since the COVID-19 crisis began.

"We know how urgently these gowns and PPE are needed in hospitals and care home," explains Guy Sultan, founder and CEO of Sultan Capital Group. "We find it deplorable to hear about long standing contracts being cancelled in favour of re-negotiated contracts that serve only to increase the profit margins of unscrupulous manufacturers. It's not something the Sultan Groups would ever do. We would never want to increase profits by increases the prices of equipment that keeps people alive and by making the essential equipment unattainable for some healthcare facilities. We have plenty of fully tested and FDA approved medical gowns and other PPE available to be shipped immediately to any facilities that need them."

While other manufacturers have increased prices and artificially inflated the prices the medical gowns, the Sultan Capital Group has not raised its prices and is on stand-by to ship the gowns around the world, wherever they may be needed.

Medical gowns and other personal protective equipment can be purchased by contacting the Sultan Capital Group at www.sultancapgroup.com. Medical gowns and other personal protective equipment are prepositioned in the Sultan Group warehouse in New York and is ready to be shipped anywhere in the United States.

For more information, or to arrange for an interview, please contact:

Guy Sultan
718-614-0944
Guy@sultancapgroup.com
www.sultancapgroup.com

SOURCE: Sultan Capital Group

ReleaseID: 594736

VANCOUVER, BC / ACCESSWIRE / June 22, 2020 / EGF THERAMED HEALTH CORP. (CSE:TMED)(OTC PINK:EVAHF)(FRANKFURT:AUHP) (the "Company") announces that its joint venture partner, Pharmadelic Labs Corp. ("Pharmadelic Labs"), in which the Company holds a 30% equity interest, has secured additional lab facility space in order to expand its research and development of proprietary processes to help create pharmaceutical grade psilocybin-derived ingredients in a synthetic lab environment.

Pharmadelic Labs has a leased space at a lab facility in Burnaby, British Columbia at a cost of $3,000 per month expiring May 1, 2021 and has begun plans for some minor retrofitting in advance of ordering/receiving DNA and certain lab equipment. Operations in Burnaby will focus on research on precursor molecules such as 4-hydroxytryptamine, norbaeocystin, baeocystin, and norpsilocin, which are not on the controlled substances list in Canada. There are also derivatives of 4-hydroxytryptamine and norpsilocin that will be pursued during this phase of research and development.

The ongoing research will focus on the genetic engineering of yeast for biosynthesis of these target molecules. Testing will be conducted using HPLC with mass spec (LC/MS) for metabolite analysis, while DNA sequencing will be used for confirmation of genetic modifications and genomic installations. Once small-scale fermentations are ready for trial there will be investigations into optimizing the metabolic pathway(s) of interest.

Pharmadelic Labs has also entered into a lease for a lab facility in Victoria, British Columbia at a cost of $5,000 per month effective August 1, 2020. The lease has an initial term of six months and is renewable at the Company's option and the satisfaction of certain conditions. The parties are currently working together reviewing lab equipment requirements in order to acquire the necessary equipment for this location. Once the lab is set-up, it is expected that Pharmadelic Labs will move all Canadian operations to Victoria and it will become their headquarters for ongoing research and development activities with precursor molecules, as well as controlled-substances, subject to drug research exemptions from the appropriate regulatory institutions.

Under the joint venture agreement, the Company has advanced funds to Pharmadelic Labs to allow it to move forward with patent filings focusing on biosynthesis of derivatives of tryptamine/psilocybin and several precursors there-in. Pharmadelic Labs is continuing to examine different DNA samples from various psilocybin producing mushrooms to determine the optimal one to use in the biosynthesis process with yeast.

As previously announced, proceeds of recent private placements have and will continue to be used, in part, for marketing and investor relations activity. The Company has recently paid USD$100,000 to Awareness Consulting Network LLC to grow awareness of the Company. This engagement for advisory services for promotional activities is on-going since May, 2020. The Company will continue to look at future marketing opportunities and strategic consultants to grow awareness of the Company and its activities.

About PHARMADELIC LABS CORP.

Pharmadelic Labs is genetically designing proprietary processes to help create pharmaceutical grade psilocybin-derived ingredients in a synthetic lab environment. Genetic engineering and biosynthesis expedite a process that creates unique modified psilocybin ingredients in a far more efficient and cost effective manner than traditional production methods.

Further information can be found at www.pharmadeliclabs.com

Mental health is one of the biggest unsolved health problems in the world. It is pervasive; it is estimated that up to one quarter of Americans can suffer a mental disorder in any given year.[1] This has a striking economic impact; treating mental health is estimated to cost the US more than $280 billion per year[2] – before economic losses due to time off work is calculated. The global antidepressants market is estimated to grow to over $22 billion by 2025[3] – this represents a huge potential market for psychedelic drugs to enter.

Current treatments such as opioids have potentially harmful side effects such as addictiveness, but psychedelic drugs like psilocybin may avoid these downsides of addiction. An article published by Johns Hopkins University in 2018 recommended that the government downgrade psilocybin's classification to Schedule IV: a drug with "low potential for abuse and low risk of dependence".[4] It has shown promising results in treating depression, as well as in palliative care.

As the government and more pharmaceutical companies recognize the medical treatment potential of psychedelic substances, it is important that access to compounds like psilocybin is made easier. Pharmadelic Labs is aiming to achieve this by creating biosynthesis pathways for psilocybin.

ABOUT EGF THERAMED HEALTH CORP.

(CSE:TMED / OTC:EVAHF / FRANKFURT: AUHP)

EGF Theramed is a consumer technology company engaged in the provision of biomedical online services for monitoring and treating common health problems. The Company, through its subsidiaries, has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations, as well as medical monitoring device technology. The Company is working to collaborate with other companies for medical technology, equipment protocols and laboratory standard operating procedures. Through the Company's recent joint venture acquisitions, it has begun to research psilocybin and psychedelic extraction and processing for commercialization.

FOR MORE INFORMATION PLEASE CONTACT:

EGF THERAMED HEALTH CORP.

Doug McFaul
Email: dmcfaul@emprisecapital.com
Telephone: (778) 331 8505
Website: http://www.theramedhealthcorp.com
CSE Micro-site: http://thecse.com/en/listings/technology/Theramed-Health-Corporation
US OTC Markets (OTCQB): http://www.otcmarkets.com/stock/EVAHF/news
Frankfurt Borse: https://www.boerse-frankfurt.de/equity/egf-theramed-health-corp

DISCLAIMERS

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including with respect to: the Company's plans for ongoing research at its lab space in Burnaby and the leased lab space in Victoria; the ability of the Company to create pharmaceutical grade psilocybin-derived ingredients in a synthetic lab environment; the ability of the Company to obtain the necessary regulatory approvals to carry out research and development on controlled substances; the effectiveness of psilocybin in treating depression or addiction; and the existence of a legal market for psilocybin in the future. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

[1] https://www.healthypeople.gov/2020/leading-health-indicators/2020-lhi-topics/Mental-Health

[2] https://www.forbes.com/sites/jonathankaufman/2019/05/15/mindset-matters-how-venture-capitalists-are-reshaping-the-landscape-of-mental-health/#11ce2587204b

[3] https://brandessenceresearch.biz/Lifesciences-and-Healthcare/Antidepressant-Drugs-Market-Size-Share-and-Forecast-to-2025/Summary

[4] https://www.ncbi.nlm.nih.gov/pubmed/29753748

SOURCE: EGF Theramed Health Corp.

ReleaseID: 594733